Preston Klassen - Net Worth and Insider Trading
Preston Klassen Net Worth
The estimated net worth of Preston Klassen is at least $759 dollars as of 2024-04-26. Preston Klassen is the President & CEO of Metacrine Inc and owns about 541,905 shares of Metacrine Inc (MTCR) stock worth over $759. Preston Klassen is the EVP and CMO of Arena Pharmaceuticals Inc and owns about 0 shares of Arena Pharmaceuticals Inc (ARNA) stock worth over $0. Preston Klassen is also the SVP, Head Global Development of Orexigen Therapeutics Inc and owns about 0 shares of Orexigen Therapeutics Inc (OREXQ) stock worth over $0. Details can be seen in Preston Klassen's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Preston Klassen has not made any transactions after 2023-01-26 and currently still holds the listed stock(s).
Transaction Summary of Preston Klassen
Preston Klassen Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Preston Klassen owns 6 companies in total, including Metacrine Inc (MTCR) , Arena Pharmaceuticals Inc (ARNA) , and Histogen Inc (HSTO) among others .
Click here to see the complete history of Preston Klassen’s form 4 insider trades.
Insider Ownership Summary of Preston Klassen
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MTCR | Metacrine Inc | 2023-01-26 | director & President & CEO |
| ARNA | Arena Pharmaceuticals Inc | 2020-03-01 | EVP and CMO |
| HSTO | Histogen Inc | 2014-02-07 | director |
| OREXQ | Orexigen Therapeutics Inc | 2016-02-02 | EVP & Global Development |
| RGLS | Regulus Therapeutics Inc | 2023-06-12 | President & Head of R & D |
| ZURA | Zura Bio Ltd | 2023-03-20 | President and COO |
Preston Klassen Latest Holdings Summary
Preston Klassen currently owns a total of 3 stocks. Among these stocks, Preston Klassen owns 541,905 shares of Metacrine Inc (MTCR) as of January 26, 2023, with a value of $759 and a weighting of 100%. Preston Klassen owns 0 shares of Arena Pharmaceuticals Inc (ARNA) as of January 8, 2019, with a value of $0 and a weighting of 0%. Preston Klassen also owns 0 shares of Orexigen Therapeutics Inc (OREXQ) as of July 25, 2013, with a value of $0 and a weighting of 0%.
Latest Holdings of Preston Klassen
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MTCR | Metacrine Inc | 2023-01-26 | 541,905 | 0.00 | 759 |
| ARNA | Arena Pharmaceuticals Inc | 2019-01-08 | 0 | 99.99 | 0 |
| OREXQ | Orexigen Therapeutics Inc | 2013-07-25 | 0 | 0.01 | 0 |
Holding Weightings of Preston Klassen
Preston Klassen Form 4 Trading Tracker
According to the SEC Form 4 filings, Preston Klassen has made a total of 3 transactions in Metacrine Inc (MTCR) over the past 5 years, including 1 buys and 2 sells. The most-recent trade in Metacrine Inc is the sale of 380,605 shares on January 26, 2023, which brought Preston Klassen around $156,048.
According to the SEC Form 4 filings, Preston Klassen has made a total of 0 transactions in Arena Pharmaceuticals Inc (ARNA) over the past 5 years. The most-recent trade in Arena Pharmaceuticals Inc is the sale of 19,000 shares on January 8, 2019, which brought Preston Klassen around $799,140.
According to the SEC Form 4 filings, Preston Klassen has made a total of 0 transactions in Orexigen Therapeutics Inc (OREXQ) over the past 5 years. The most-recent trade in Orexigen Therapeutics Inc is the sale of 7,123 shares on July 25, 2013, which brought Preston Klassen around $510,000.
Insider Trading History of Preston Klassen
- 1
Preston Klassen Trading Performance
GuruFocus tracks the stock performance after each of Preston Klassen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Preston Klassen is -29.46%. GuruFocus also compares Preston Klassen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Preston Klassen within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Preston Klassen's insider trading performs compared to the benchmark.
Performance of Preston Klassen
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 7.3 | -29.46 | -65.68 | -88.46 | -60.89 | |
| Relative Return to S&P 500(%) | 7.12 | -36.25 | -78.64 | -82.26 | -61.28 |
Preston Klassen Ownership Network
Ownership Network List of Preston Klassen
Ownership Network Relation of Preston Klassen
Preston Klassen Owned Company Details
What does Metacrine Inc do?
Who are the key executives at Metacrine Inc?
Preston Klassen is the director & President & CEO of Metacrine Inc. Other key executives at Metacrine Inc include Chief Business Officer Michael York , 10 percent owner Braden Michael Leonard , and 10 percent owner Carmen Chang .
Metacrine Inc (MTCR) Insider Trades Summary
Over the past 18 months, Preston Klassen made 1 insider transaction in Metacrine Inc (MTCR) with a net sale of 380,605. Other recent insider transactions involving Metacrine Inc (MTCR) include a net purchase of 1,248,404 shares made by Braden Michael Leonard , a net sale of 107,054 shares made by Michael York ,
In summary, during the past 3 months, insiders sold 0 shares of Metacrine Inc (MTCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 487,659 shares of Metacrine Inc (MTCR) were sold and 1,248,404 shares were bought by its insiders, resulting in a net purchase of 760,745 shares.
Metacrine Inc (MTCR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Metacrine Inc Insider Transactions
Preston Klassen Mailing Address
Above is the net worth, insider trading, and ownership report for Preston Klassen. You might contact Preston Klassen via mailing address: 3344 N. Torrey Pines Court, Suite 200, La Jolla Ca 92037.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
